Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
- Authors: Savelyeva MI1,2, Ignatova AK2, Panchenko Y.S2, Urvantseva IA2, Poddubnaya IV1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 2 (2017)
- Pages: 28-32
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27135
- ID: 27135
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
M I Savelyeva
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Email: marinasavelyeva@mail.ru
д-р мед. наук, проф. каф. клин. фармакологии и терапии ФГБОУ ДПО РМАНПО, проф. каф. патологии человека ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1; 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
A K Ignatova
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationстудентка 4-го курса фак-та «Медицина будущего» ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
Yu S Panchenko
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationстудентка 4-го курса фак-та «Медицина будущего» ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
I A Urvantseva
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationстудентка 4-го курса фак-та «Медицина будущего» ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
I V Poddubnaya
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federationакад. РАН, д-р мед. наук, проф., зав. каф. онкологии, проректор по учебной работе и международному сотрудничеству ФГБОУ ДПО РМАНПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
References
- Burstein H.J, Griggs J.J, Prestrud A.A, Temin S. American Society of Clinical Oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor - positive breast cancer. J Oncol Pract 2010; 6 (5): 243-6.
- Forrest A.R. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 349: 1090.
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient - level meta - analysis of randomised trials. Lancet 2011; 378: 771-84.
- Lim Y.C, Desta Z, Flockhart D.A, Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti - estrogenic effects in breast cancer cells with potency similar to 4-hydroxy - tamoxifen. Cancer Chemother Pharmacol 2005; 55: 471-8.
- Johnson M.D1, Zuo H, Lee K.H et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-9.
- Desta Z, Ward B.A, Soukhova N.V, Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-75.
- NCCN Clinical Practice Guidelines in Oncology. Breast cancer version 2.2017 - April 6, 2017.
- Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97:30-9.
- Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
- Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-93.
- Brauch H, Mürdter T.E, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009; 55: 1770-82.
- Desta Z, Ward B.A, Soukhova N.V, Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-75.
- Brauch H, Mürdter T.E, Eichelbaum M, Schwab M. Pharmacogenomics of Tamoxifen Therapy. Clinical Chemistry 2009; 55 (10): 1770-82.
- Human cytochrome P450 (CYP) allele nomenclature T. The Human Cytochrome P450 (CYP) Allele Nomenclature Database.
- Gjerde J, Geisler J, Lundgren S et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010; 10: 313.
- Zafra-Ceres M, de Haro T, Farez-Vidal E et al. Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer. Int J Med Sci 2013; 10: 932-7.
- Powers J.L, Buys S.S, Fletcher D et al. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. J Clin Pharmacol 2016; 56: 1570-81.
- Lim J.S, Chen X.A, Singh O et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 2011; 71: 737-50.
- Mürdter T.E, Schroth W, Bacchus-Gerybadze L et al; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-17.
- Saladores P, Mürdter T, Eccles D et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 2015; 15: 84-94.
- Lim J.S, Sutiman N, Muerdter T.E et al. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen - treated Asian breast cancer patients. Br J Clin Pharmacol 2016; 81: 1142-52.
- Lu W.J, Desta Z, Flockhart D.A. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 2012; 131: 473-81.
- Lu W.J, Xu C, Pei Z et al. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2012; 133: 99-109.
- Lv W.J, Liu J, Lu D et al. Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem 2013; 56: 4611-8.
- Wei Lv, Jinzhong Liu, Skaar T.C et al. Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities. J Med Chem 2015; 58: 2623-48.
- Okishiro M, Taguchi T, Jin Kim S et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009; 1 (115): 952-61.
- Mwinyi J, Vokinger K, Jetter A et al. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol 2014; 73: 1181-8.
- Moyer A.M, Suman V.J, Weinshilboum R.M et al. SULT1A1, CYP2C19 and disease - free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 2011; 12: 1535-43.
- Chamnanphon M, Pechatanan K, Sirachainan E et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease - free survival of Thai post - menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med 2013; 6: 37-48.
- Ruiter R, Bijl M.J, van Schaik R.H et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 2010; 11: 1367-75.
- Beelen K, Opdam M, Severson T.M et al. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat 2013; 139: 649-55.
- Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-93.
- Schaik R.H, Kok M, Sweep F.C et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 2011; 12: 1137-46.
- Bai L, He J, He G.H et al. Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta - analysis. Asian Pac J Cancer Prev 2014; 15: 8331-5.
- Justenhoven C, Hamann U, Pierl C.B et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009; 115: 391-6.